Meeting NewsVideo

VIDEO: Novel anti-VEGF therapy shows ‘promising’ durability for wet AMD

SAN FRANCISCO — In a new phase 1b trial, KSI-301, an antibody biopolymer conjugate that blocks VEGF isoforms, demonstrated strong durability and safety for the treatment of wet age-related macular degeneration, as well as diabetic macular edema and retinal vein occlusion, according to a speaker at the American Academy of Ophthalmology annual meeting.

“One of the biggest challenges in retina right now is the durability of our anti-VEGF agents,” Charles C. Wykoff, MD, PhD, told Ocular Surgery News. “They work extremely well, and many patients have done very well with them, but repeated injections are a significant burden for patients.”

In the trial, most patients went at least 3 months without requiring retreatment after the last of three loading doses with no intraocular inflammation or adverse events, he said.

“The caveats here are this is still an early stage development ... but it is very promising from a durability perspective,” Wykoff said. – by Alaina Tedesco

Reference: Wykoff CC. Extended durability in exudative retinal diseases using the novel intravitreal anti-VEGF antibody biopolymer conjugate KSI-301: Results from the phase 1b study in patients with wAMD, DME and RVO. Presented at: American Academy of Ophthalmology Annual Meeting; Oct. 11-15, 2019; San Francisco.

Disclosure: Wykoff reports consulting for Kodiak Sciences.

SAN FRANCISCO — In a new phase 1b trial, KSI-301, an antibody biopolymer conjugate that blocks VEGF isoforms, demonstrated strong durability and safety for the treatment of wet age-related macular degeneration, as well as diabetic macular edema and retinal vein occlusion, according to a speaker at the American Academy of Ophthalmology annual meeting.

“One of the biggest challenges in retina right now is the durability of our anti-VEGF agents,” Charles C. Wykoff, MD, PhD, told Ocular Surgery News. “They work extremely well, and many patients have done very well with them, but repeated injections are a significant burden for patients.”

In the trial, most patients went at least 3 months without requiring retreatment after the last of three loading doses with no intraocular inflammation or adverse events, he said.

“The caveats here are this is still an early stage development ... but it is very promising from a durability perspective,” Wykoff said. – by Alaina Tedesco

Reference: Wykoff CC. Extended durability in exudative retinal diseases using the novel intravitreal anti-VEGF antibody biopolymer conjugate KSI-301: Results from the phase 1b study in patients with wAMD, DME and RVO. Presented at: American Academy of Ophthalmology Annual Meeting; Oct. 11-15, 2019; San Francisco.

Disclosure: Wykoff reports consulting for Kodiak Sciences.

    See more from Discoveries from AAO: AMD